Entrectinib is a targeted cancer therapy belonging to a class of drugs known as tyrosine kinase inhibitors. It is specifically designed to inhibit the activity of certain proteins known as TRK, ROS1, and ALK, which are involved in the growth and proliferation of cancer cells. By targeting these proteins, entrectinib can help to slow down or stop the growth of cancer.
